Kane Biotech

Kane Biotech Net Debt/FCF

The Net Debt to Free Cash Flow Ratio of Kane Biotech (KNE.V) as of Nov 18, 2026 is -0.18. In the previous year, Net Debt to Free Cash Flow Ratio was -0.23 — a change of -19.67% (higher).

Net Debt/FCF

-0.18

YoY

-19.67%

Last updated:

Net Debt to Free Cash Flow Ratio of Kane Biotech is 2025 -0.18 . Net Debt to Free Cash Flow Ratio of Kane Biotech was 2024 -0.23 . It decreases by -19.67% higher compared to the previous year.

The Kane Biotech Net Debt/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt/FCF
Date
Net Debt/FCF
Jan 1, 2018
-0.14 CAD
Jan 1, 2019
0.63 CAD
Jan 1, 2020
-0.31 CAD
Jan 1, 2021
-1.35 CAD
Jan 1, 2022
-1.84 CAD
Jan 1, 2023
-3.97 CAD
Jan 1, 2024
-0.23 CAD
Jan 1, 2025
-0.18 CAD
The Kane Biotech Net Debt/FCF history
YEARNet Debt/FCFYoY
-0.18-19.67%
-0.23-94.25%
-3.97+116.06%
-1.84+36.30%
-1.35+341.13%
-0.31-148.42%
0.63-545.92%
-0.14-115.75%
0.90+810.01%
0.10-145.88%
-0.22-151.38%
0.42—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Kane Biotech Stock analysis

What does Kane Biotech do? Kane Biotech, Inc. generates revenue through its portfolio of biotechnology products designed to prevent and remove microbial biofilms. The company commercializes StrixNB, DispersinB, Aledex, bluestem, silkstem, goldstem, coactiv+, and DermaKB Biofilm, with specific focus on the Wound Care & Surgical division developing DispersinB for chronic wound care. The bluestem product line targets animal health markets with water additives, chews, spray, and dental wipes, while Coactiv+ and DispersinB Gel are in development for antimicrobial wound rinse and prosthetic joint infection applications. Additional products include Scalp Detoxifier, Shampoo, and Shampoo Bars for consumer use. Kane Biotech serves animal health markets through its bluestem product line, which includes water additives, chews, spray, and dental wipes. The Wound Care & Surgical division targets medical applications, focusing on DispersinB for chronic wounds and developing Coactiv+ for antimicrobial wound rinse and surgical hydrogel. Consumer products like Scalp Detoxifier, Shampoo, and Shampoo Bars cater to personal care segments. The company's development-stage products such as Coactiv+ antimicrobial surgical hydrogel and DispersinB Gel for prosthetic joint infection represent future revenue streams. The company's primary markets include animal health for bluestem products, medical applications for Wound Care & Surgical division, and consumer personal care for Scalp Detoxifier and Shampoo products. DispersinB is central to the medical division, while bluestem dominates the animal health segment. Development-stage products like Coactiv+ and DispersinB Gel are positioned to address unmet needs in wound care and prosthetic infections, expanding the company's market reach into specialized medical and consumer health segments. Kane Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Kane Biotech stock

Net Debt to Free Cash Flow Ratio of Kane Biotech is -0.18 in 2025.

Net Debt to Free Cash Flow Ratio of Kane Biotech changed from -0.23 to -0.18, representing a -19.67% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to Free Cash Flow Ratio Kane Biotech since 2006 – with annual values, charts, and detailed analysis.

Net Debt/FCF indicates how many years it would take to repay net debt using free cash flow. Lower ratios suggest faster deleveraging potential.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to Free Cash Flow Ratio's Kane Biotech with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Kane Biotech

All Key Metrics — Kane Biotech